Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SKYE Stock Forecast 2025-2026
$1.14
Current Price
$36.55M
Market Cap
Buy 6
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to SKYE Price Targets
+1,654.4%
To High Target of $20.00
+557.9%
To Median Target of $7.50
+75.4%
To Low Target of $2.00
SKYE Price Momentum
-5.8%
1 Week Change
-21.9%
1 Month Change
-68.5%
1 Year Change
-59.7%
Year-to-Date Change
-80.2%
From 52W High of $5.75
+3.6%
From 52W Low of $1.10
📊 TOP ANALYST CALLS
Did SKYE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Skye Bioscience is one of their latest high-conviction picks.
Latest SKYE Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, SKYE has a bullish consensus with a median price target of $7.50 (ranging from $2.00 to $20.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $1.14, the median forecast implies a 557.9% upside. This outlook is supported by 6 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ananda Ghosh at HC Wainwright & Co., projecting a 1,654.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SKYE Analyst Ratings
6
Buy
2
Hold
0
Sell
SKYE Price Target Range
Low
$2.00
Average
$7.50
High
$20.00
Current: $1.14
Latest SKYE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SKYE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. | Ananda Ghosh | Buy | Initiates | $20.00 |
| Aug 15, 2025 | Evercore ISI Group | Michael DiFiore | Outperform | Initiates | $10.00 |
| Jun 24, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $15.00 |
| Mar 21, 2025 | Craig-Hallum | Albert Lowe | Buy | Maintains | $14.00 |
| Mar 21, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $15.00 |
| Feb 28, 2025 | William Blair | Andy Hsieh | Outperform | Initiates | $N/A |
| Sep 30, 2024 | Scotiabank | George Farmer | Sector Outperform | Initiates | $20.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Sep 20, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $20.00 |
| Sep 10, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Initiates | $15.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Sep 6, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Aug 27, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Jul 9, 2024 | Craig-Hallum | Albert Lowe | Buy | Initiates | $18.00 |
| Jul 1, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Jun 18, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Jun 17, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| May 23, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Initiates | $21.00 |
| Apr 12, 2024 | Oppenheimer | Jay Olson | Outperform | Initiates | $25.00 |
| Mar 14, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $20.00 |
Skye Bioscience Inc. (SKYE) Competitors
The following stocks are similar to Skye Bioscience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SKYE
Skye Bioscience
mkt cap
38.47M
Skye Bioscience Inc. (SKYE) Financial Data
Skye Bioscience Inc. has a market capitalization of $36.55M with a P/E ratio of 3.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -94.3%.
Valuation Metrics
Market Cap
$36.55M
Enterprise Value
$3.48M
P/E Ratio
3.6x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+96.7%
Current Ratio
4.8x
Debt/Equity
1.0x
ROE
-94.3%
ROA
-54.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Skye Bioscience Inc. (SKYE) Business Model
About Skye Bioscience Inc.
What They Do
Develops cannabinoid-based pharmaceuticals for eye diseases.
Business Model
Skye Bioscience generates revenue by developing and commercializing novel pharmaceuticals that incorporate cannabinoids, specifically targeting the treatment of eye conditions such as glaucoma. The company focuses on addressing unmet medical needs within the ophthalmology sector, which allows it to tap into a niche market with significant growth potential.
Additional Information
As a biotechnology firm, Skye Bioscience operates in a sector characterized by rapid advancements and increasing interest in alternative therapies. The company is well-positioned to benefit from evolving regulatory landscapes surrounding cannabis-derived compounds, which could lead to expanded opportunities for innovation and market penetration.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Mr. Punit S. Dhillon B.A.
Country
United States
IPO Year
2021
Website
skyebioscience.comSkye Bioscience Inc. (SKYE) Latest News & Analysis
Latest News
Quick Summary
A class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) for securities violations. Affected investors from Nov 4, 2024, to Oct 3, 2025, should contact Schall Law Firm by Jan 16, 2026.
Why It Matters
The class action lawsuit against Skye Bioscience signals potential legal and financial risks, which could impact share prices and investor sentiment regarding the company's future.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky, LLP has filed a class action lawsuit for Skye Bioscience, Inc. (NASDAQ: SKYE) on behalf of investors affected by alleged securities fraud from November 4, 2024, to October 3, 2025.
Why It Matters
A class action lawsuit against Skye Bioscience for alleged securities fraud may lead to financial losses for investors, affecting stock value and market confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE) as of December 8, 2025.
Why It Matters
The notice could indicate legal issues or shareholder actions involving Skye Bioscience, potentially affecting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm alerts investors in Skye Bioscience (NASDAQ: SKYE) who purchased securities between Nov 4, 2024, and Oct 3, 2025, of a January 16, 2026 lead plaintiff deadline.
Why It Matters
The announcement signals potential legal issues for Skye Bioscience, which could affect stock performance and investor sentiment during the class period.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Gross Law Firm is inviting Skye Bioscience, Inc. (NASDAQ: SKYE) shareholders to contact them about potential lead plaintiff appointments for a class action.
Why It Matters
Shareholder notices indicate potential legal actions affecting Skye Bioscience, which can impact stock performance and investor sentiment, influencing trading decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Skye Bioscience, Inc. for investors who acquired securities from Nov 4, 2024, to Oct 3, 2025. Deadline to seek lead plaintiff status is Jan 16, 2026.
Why It Matters
The class action lawsuit against Skye Bioscience signals potential legal and financial risks, which could impact stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SKYE Stock
What is Skye Bioscience Inc.'s (SKYE) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Skye Bioscience Inc. (SKYE) has a median price target of $7.50. The highest price target is $20.00 and the lowest is $2.00.
Is SKYE stock a good investment in 2026?
According to current analyst ratings, SKYE has 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SKYE stock?
Wall Street analysts predict SKYE stock could reach $7.50 in the next 12 months. This represents a 557.9% increase from the current price of $1.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Skye Bioscience Inc.'s business model?
Skye Bioscience generates revenue by developing and commercializing novel pharmaceuticals that incorporate cannabinoids, specifically targeting the treatment of eye conditions such as glaucoma. The company focuses on addressing unmet medical needs within the ophthalmology sector, which allows it to tap into a niche market with significant growth potential.
What is the highest forecasted price for SKYE Skye Bioscience Inc.?
The highest price target for SKYE is $20.00 from Ananda Ghosh at HC Wainwright & Co., which represents a 1,654.4% increase from the current price of $1.14.
What is the lowest forecasted price for SKYE Skye Bioscience Inc.?
The lowest price target for SKYE is $2.00 from at , which represents a 75.4% increase from the current price of $1.14.
What is the overall SKYE consensus from analysts for Skye Bioscience Inc.?
The overall analyst consensus for SKYE is bullish. Out of 9 Wall Street analysts, 6 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $7.50.
How accurate are SKYE stock price projections?
Stock price projections, including those for Skye Bioscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 4:07 AM UTC